February 27, 2025 — More than a decade ago, targeting amylin receptors for treating obesity looked like hot opportunity. Amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells, plays a role in regulating satiety and food intake. An amylin analog, pramlintide, gained FDA approval for treating diabetes. But efforts to develop it for treating obesity never quite […]
February 7, 2025 — Novo Nordisk and Lilly reported on their business results this week for the final quarter of 2024. These reports brought clarity on a number of points, but to us, one thing stands out. We are moving from euphoria and hype about limitless possibilities in obesity to the realities of market competition and incremental progress. Sales […]
January 25, 2025 — The race to innovate beyond semaglutide and tirzepatide for obesity can be utterly confusing. More than a hundred new drugs are in various stages of development and analysts expect more than a dozen to be launched within the next five years. But right now, all we have are tantalizing – and sometimes disappointing – results […]
September 12, 2024 — The obesity buzz of the day at EASD annual meeting is clearly amycretin. Amycretin is a new oral medication under study for obesity that activates both GLP-1 and amylin receptors. The excitement came because this is the first public presentation of clinical data on amycretin. This news is impressive on two counts. First, the dosage […]
March 13, 2024 — The drug development pipeline is filling up with new new drugs for weight loss or obesity. On Thursday, Novo Nordisk caused the hearts of investors to flutter when it presented topline results on an oral medicine that might be more effective than semaglutide. The value of the company’s stock jumped by 13%. Just a week […]
